Principal Investigator: Paul Gordon, MD
Sponsored by: Amorcyte, LLC
Subjects who have suffered a heart attack and have damaged the heart muscle will be considered to be part of this investigational study. The rationale behind this study is to determine if stem cell therapy can decrease life-time risk of experiencing adverse cardiac events, including death. Subjects will have a mini-bone marrow harvest between 4 and 9 days after having a stent placed in the infarct related artery. Within 72 hours after the bone marrow harvest, the subject will return to the hospital for a repeat cardiac catheterization procedure and receive the infusion of AMR-001 into the artery that just had a stent placed in it. Subjects will be followed for approximately 3 years and will have physical exams several times during the study period.
Cardiovascular ResearchThe Miriam HospitalLori-Ann DeSimone, RN401-793-4105